Annette E. Hay

The economic impact of the transition from branded to generic oncology drugs.

D. Tu, R. Ng, E. A. Kornelsen, 2019, Current Oncology.

Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the phase III CCTG LY.12 trial

K. Davison, V. Kukreti, M. Crump, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12.

Bingshu E. Chen, V. Kukreti, M. Crump, 2015, Journal of the National Cancer Institute.

Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada.

J. Pater, C. O'Callaghan, N. Leighl, 2016, Current oncology.